about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Af­ter pre­sid­ing over stormy years, John McHutchi­son picks his 's­trate­gic part­ner' to run As­sem­bly Bio

3 years ago
People

Mer­ck­'s $500M bet on Sin­ga­pore leads to new man­u­fac­tur­ing sites mak­ing Keytru­da, Gar­dasil and fu­ture in­halers

3 years ago
Pharma
Manufacturing

GSK touts topline win for PD-1 in head-to-head with Keytru­da — while steer­ing next big check­point drug in­to PhI­II

3 years ago
R&D

Amy­lyx snatched the land­mark ap­proval for its ALS drug. Now it’s seek­ing cash to foot the launch bill

3 years ago
Financing

Land­mark Amy­lyx OK spurs de­bate; Some... pos­i­tive? Alzheimer's da­ta; Can­cer tri­al bot­tle­neck; Sanofi's CRISPR bet; ...

3 years ago
Weekly

Bio­Marin re­turns to FDA with a new pitch for he­mo­phil­ia gene ther­a­py — and a promise to get to the bot­tom of ...

3 years ago
Cell/Gene Tx
FDA+

As lead drug flopped and Ab­b­Vie col­lab dis­solved, can­cer biotech re­sorts to buy­ing rare dis­ease com­pa­ny

3 years ago
Deals

No­vo Nordisk joins No­var­tis, Roche in NL­RP3 are­na, bet­ting $70M cash on NASH, car­diometa­bol­ic us­es

3 years ago
Deals

For­mer No­var­tis drug for ul­tra-rare dis­ease gets speedy FDA re­view

3 years ago
FDA+

Now play­ing catch-up to blue­bird, Ver­tex and CRISPR send in their pitch for blood dis­or­der cell ther­a­py

3 years ago
Cell/Gene Tx
FDA+

In sur­vival mode, Ex­i­cure cuts to the bone — paus­ing all R&D and chop­ping head­count by 66%

3 years ago
People
R&D

Ar­cutis' for­mu­la­tion of old As­traZeneca drug clears an­oth­er PhI­II test

3 years ago
R&D

With con­sumer health be­hind it, GSK taps As­traZeneca vet Julie Brown as CFO for R&D-fo­cused fu­ture

3 years ago
People

The End­points 11; blue­bird's $3M gene ther­a­py; Bio­gen tout new neu­ro da­ta; Harsh re­views for can­cer drugs; and more

3 years ago
Weekly

As­traZeneca shuts the PhI­II door for Ion­is' PC­SK9 drug de­spite pos­i­tive PhI­Ib

3 years ago
R&D

Up­dat­ed: Eli Lil­ly's RET drug notch­es tu­mor-ag­nos­tic ac­cel­er­at­ed ap­proval, full FDA OK in NSCLC

3 years ago
Pharma
FDA+

Lend­ing a hand to a biotech in trou­ble, GSK drops $75M cash to add late-stage an­tibi­ot­ic to port­fo­lio

3 years ago
Deals

Take­da punts dis­ap­point­ing late-stage Mil­len­ni­um drug for $7M in cash

3 years ago
R&D

Two CRLs lat­er, FDA en­dors­es drug to pre­vent hear­ing loss as­so­ci­at­ed with chemo

3 years ago
Pharma
FDA+

In wake of safe­ty scare, Mer­ck scraps month­ly PrEP plans for lead HIV drug — while march­ing ahead with re­vised ...

3 years ago
R&D

Months af­ter launch­ing with lofty goal, Flag­ship start­up stream­lines ops, chops head­count

3 years ago
People

As Gami­da Cell eyes its first cell ther­a­py ap­proval, Ju­lian Adams is head­ing out

3 years ago
People

Blue­bird lands an­oth­er rare dis­ease gene ther­a­py OK — but there are a few caveats to note

3 years ago
Pharma
Cell/Gene Tx

On heels of Lumakras da­ta drop, new KRAS idea emerges; Bris­tol My­ers, Ab­b­Vie, Ru­bius head­line busy week of ...

3 years ago
Weekly
First page Previous page 23242526272829 Next page Last page
A service from the Financial Times